As shown in Figure 5C, markedly higher CD86 expressions were demonstrated in Grade-III glioma with wild-type (WT) isocitrate dehydrogenase (IDH) compared with IDH mutant (P<0.001), while no between-group significance was observed in Grade-II glioma. This evidence concerns the gene CD86 and central nervous system cancer.